As per market grapevine, crude oil needs to remain below US$80/barrel for sustained strength in Indian equities. Till then, selling on rallies may continue. Focus on fundamentally strong growth stocks that report robust Q1FY27 EBITDA and PAT with positive Q2FY27 guidance.

Captain Polyplast received a Rs.23.6 crore order from (inclusive of GST) from Maharashtra State Electricity Distribution Co Ltd. for 1,000 off-grid DC solar water pumping systems under the PM-KUSUM B Scheme.

Rajesh Power reported FY26 PAT of Rs.143 cr. and EPS of Rs.80, with ROCE of 48.6%. Its order book stands at Rs.2925 cr., with recent wins worth Rs.887 cr. and entry into Battery Energy Storage Systems (BESS). Trading at Rs.865 versus its 52-week high of Rs.1639, the stock appears attractive.

On Friday, 17-7-2026, Huhtamaki India witnessed a bullish breakout with volumes of 436,094 shares. The stock looks attractive at Rs.237 against its lifetime high of Rs.452. Keep it on the radar ahead of its Q1 results on 21-7-2026.

India Pesticides has received Technical Equivalence (TEQ) approval in the European Union for one of its fungicide products, strengthening its international presence. Keep the stock on the radar.

SpaceX aborted the second Starship V3 launch after ignition. The stock has declined nearly 45% from its all-time high of $225 to around $124, below its IPO price of $135, highlighting how hype and FOMO can erode investor wealth.

Trend Over Valuation – Prices lead valuations, not vice versa. Respect the trend, ignore market noise and remember that fundamentally strong stocks often shake out weak holders before resuming their long-term uptrend. Patience and discipline remain the key to wealth creation.

Astrology View – Important turning dates are 20, 22, 27, 29 & 31 July 2026. Stock-specific volatility may remain high till 18 August. Trade with strict stop-losses, disciplined position sizing and avoid excessive leverage.

Emerald Finance expanded its Early Wage Access (EWA) network by onboarding Vertex Industries, strengthening its salary advance platform.

Morepen Laboratories is a leading API and formulations player with exports to over 90 countries. It recently received USFDA clearance with NIL Form 483 and secured a Rs.825 crore CDMO order, with another Rs.225 crore expected in Q2FY27. The stock looks attractive at Rs.61 against its lifetime high of Rs.222.